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Tommaso Claudio Mineo1*, Vincenzo Ambrogi1 and Orazio Schillaci2Abstract
Background: In myasthenia gravis (MG) both native and ectopic thymic tissue containing germinal centers should
show greater metabolism compared to adjacent tissues. We evaluated whether preoperative standardized uptake
value (SUV) of 18fluoro-deoxy-glucose on Positron Emission Tomography (PET) might be increased and correlated
with the presence of native or ectopic germinal centers.
Methods: From 2005 to 2012 we performed extended thymectomy in 68 patients with non-thymomatous MG. All
patients underwent PET-scan preoperatively and one-year postoperatively. SUVs were assessed in thymic and
perithymic regions. Then it was matched with same-age, non-MG and non-neoplastic control group and finally
correlated with presence of germinal centers in native thymus or in the ectopic tissue found in the surgical specimens.
Results: Mean SUV was significantly increased in MG patients compared to control group. Thymic SUV was significantly
higher in presence of thymic germinal centers [3.5 (2.4-5.0) Vs 2.1 (1.4-2.5), p = 0.021] while perithymic SUV was
significantly higher in presence of ectopic germinal centers [3.1 (2.7-3.5) Vs 1.3 (0.9-1.7), p = 0.001]. SUV was significantly
correlated with MG score (rho = 0.289, p = 0.017) and marginally with antibodies anti-acetylcholine receptors
(rho = 0.129, p = 0.05). At Kaplan Meier analysis, ectopic thymic tissue (p = 0.045) and ectopic germinal centers
(p = 0.036) were significant predictors of complete stable remission, but preoperative dichotomized thymic
(3.5 or more Vs less) (p = 0.083) and perithymic (2.1 or more Vs less) (p = 0.052) SUVs did not.
Conclusions: Thymic and perithymic SUVs were significantly higher in patients with MG than non-MG and
non-neoplastic patients. Thymic SUV was significantly correlated with the presence of germinal centers.
Perithymic SUV resulted significantly correlated with the discovery of ectopic active thymic tissue. Neither thymic nor
perithymic high SUVs predicted remission.
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Extended thymectomy is considered one of the key points
for achieving complete stable remission of myasthenia
gravis (MG) [1-4]. The persistence of ectopic thymic tis-
sue hosting germinal centers and producing antibodies
against acetylcholine receptors (anti-AchR Ab) is sup-
posed to be one of the main reasons of poor outcome* Correspondence: mineo@med.uniroma2.it
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unless otherwise stated.after thymectomy [5-12]. Positron Emission Tomography
(PET) is a radiological device that utilizes 18fluoro-deoxy-
glucose (18FDG) to study the metabolism of organs and
tissues [13]. It is successfully used to investigate neo-
plastic masses and for staging purposes by quantifying
the pathologic elevation of metabolism in a rapid
growing tissue [14].
We hypothesized that in MG patients, the germinal
centers contained in both the native and ectopic thymic
tissue appear metabolically more active than surrounding
tissues. This feature might imply an increased consumption
of glucose in these areas and a consequent high stan-
dardized uptake value (SUV) on PET.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Main demographic and clinical features of the
study group
Variables p-value (n = 68)
Age, years (median IQR) 39 (25–59)
Gender
Male, n. pts (%) 31 (45) 0. 6
Female, n. pts (%) 37 (55)
Anti AchR Ab, nmol/L (median IQR) 3.1 (2.0-4.0)
Score MG (median IQR) 23 (14–29)
Symptom duration
<12 months, n. pts (%) 20 (29) 0.69
≥12 months, n. pts (%) 48 (71)
Oropharyngeal symptoms
Yes, n. pts (%) 36 (53) 0.91
No, n. pts (%) 32 (47)
MGFA classification
Class I, n. pts (%) 6 (9) 0.06
Class II, n. pts (%) 40 (59)
Class III, n. pts (%) 22 (32)
Histology
Hyperplasia, n. pts (%) 27 (40) 0.89
Atrophia, n. pts (%) 23 (34)
Normal, n. pts (%) 18 (26)
Thymic germinal centers, n. pts (%) 33 (48)
Ectopic tissue, n. pts (%) 37 (54)
Ectopic germinal centers, n. pts (%) 23 (34)
Values are represented as number of patients (percentage) or median and
interquartile range (IQR).
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iables related to the disease and, namely, with the presence
of germinal centers in both the native and ectopic thymic
tissue. Furthermore, we also investigated the possible influ-
ence of SUV on clinical outcome after thymectomy.
Methods
PET is an investigation based on the intravenous adminis-
tration of short-duration radionuclides. It is mainly used
for diagnostic purposes in neoplastic diseases. For its off-
label utilization in a benign condition we asked and ob-
tained a legal permission issued by the “Comitato Etico”
(ethical board of our Institution) (prot. No. CT/2004/
0396). Each patient was adequately informed about the
purposes of the study as well as pros and cons of a
radionuclide-based analysis and released written and fully
informed consent to the use of PET.
Patients
Our study included a total of 68 consecutive myasthenic
non-thymomatous patients, 37 females and 31 males,
aged from 15 to 74 years (mean 41.1 ± 16.6), who under-
went extended thymectomy in our multidisciplinary Unit
between 2005 and 2012. Major demographic data are
summarized in Table 1.
Study design
This study was designed as a retrospective non-randomized
investigation. Only patients with non-thymomatous MG up
to Class III according to the MG Foundation of America
were included [15]. All patients with thymoma were
excluded from the study.
Data were prospectively collected evaluating the surgical
details, postoperative complications, histological type,
characteristics of postoperative treatment, all information
concerning MG (class, MG score, presence of bulbar
symptoms, myasthenic crisis, steroid use, blood levels of
anti-AchR Ab) and all information regarding the evolution
and the date of the possible complete stable remission
(CSR). The study entailed the use of archival material such
as medical records, radiographs, histological specimens
and lab tests, the use of whom was approved by the
“Comitato etico” (prot.no. PTV/2011/01522) involved in
this investigation.
MG assessment
The diagnosis of MG was based on clinical features and
one or more of the following criteria: positive single-
fiber repeated stimulation electromyography, demonstra-
tion of circulating anti-AchR Ab and response to edro-
phonium chloride. A quantitative MG score from 0 (no
impairment) to 39 (maximum impairment) was also evalu-
ated pre- and postoperatively [16]. Before thymectomy, allpatients were receiving anticholinesterase drugs alone or
in combination with steroids (n = 12).
A medical panel composed of neurologists, thoracic
surgeons and anesthesiologists discussed the decision
and timing for thymectomy. Each patient was clinically
stable before surgery. The surgical approach (sternotomy
Vs video-thoracoscopy) was chosen by the patients after
fully information. In case of increasing weakness or
bulbar symptoms, plasmapheresis (n = 2) or intravenous
immunoglobulins (n = 3) were administrated immediately
prior to surgery.
PET imaging
The PET/Computed Tomography (CT) system Discovery
ST16 (GE Medical Systems, Milwaukee, WI, USA) was
used to assess 18FDG distribution in all patients by 3D-
mode standard technique in a 128x128 matrix. Filtered
back projection was used for image reconstruction. Axial
full width at half maximum 1 cm radius 5.2 mm in 3D
mode, axial field of view 157 mm. All patients fasted for at
least 5 hours before 18FDG intravenous injection. All the
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410 MBq) of 18FDG intravenous and hydrated with
500 mL of intravenous normal saline solution. Whole
body PET/CT scan was performed around 60 minutes
after 18FDG injection. A low-amperage whole body CT
scan for attenuation correction (40 mA; 120 Kv) was per-
formed before PET image acquisition according to stand-
ard guidelines [17].
All PETs were reviewed independently by three nuclear
med physicians (including OS) Maximum SUV of the
thymic and perithymic regions was separately calculated
on a dedicated workstation for all the PET/CT examina-
tions. The readers’ independent scores from the PET/CT
reading were averaged for each region and the final max-
imum value was simply indicated in the text as SUV
(Figure 1). The images were evaluated without know-
ledge of patient’s identity, clinical history or subsequentFigure 1 Positron Emission Tomography images. (A) normal thymus, (B)
value, (C) non-thymomatous myasthenic thymus with an area of higher stafollow-up. For thymus, a volume of interest has been
traced on the thymic tissue and all the volumes of
interest were furthermore checked in a three planar
view in order to exclude the inclusion of unwanted tis-
sues in the area of interest (i.e. vessels, heart wall). For
mediastinal perithymic fatty tissue, a standard volume
of interest 1x1x1cm (for a total volume of 1 cm3) was
placed on the mediastinal fat. In order to exclude any
partial volume effect, the contrast enhanced CT images
were used for a better overall anatomical definition and
for a correct volume of interest placement.
Surgical technique
All the procedures were accomplished under general
anesthesia with single-lung ventilation, and were carried
out by a single surgeon (TCM). Thymectomy was per-
formed through transsternal (n = 47) or left video-assistednon-thymomatous myasthenic thymus with elevated standard uptake
ndard uptake value in a perithymic region (arrows).
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was chosen according to patient’s preferences after fully
informed consent. Only short-acting, nondepolarizing
neuromuscular relaxants were occasionally used. Pyrido-
stigmine was administered during the operation and up to
12 hours afterwards through a nasogastric tube. All surgical
steps are described elsewhere [10,18]. Resection routinely
included perithymic fat tissue from anterior mediastinum,
neck, aorto-caval groove, aorto-pulmonary window, retro-
innominate space, and both cardiophrenic angles. Thymec-
tomy was considered extended according to Sonnet and
Jaretzki [19].
At the end of the operation, we encouraged early
extubation of the patients and rapid physiotherapy. Pain
control was preferentially performed by means of oral
analgesics only. Anticholinesterase drugs and steroids
were administrated according to clinical status.Thymic specimen evaluation
Histological examination of all excised tissue was described
elsewhere [10]. Classic hematoxylin and eosin-stained sec-
tions were firstly examined under low magnification (×20).
Ectopic thymus was randomly researched by taking 1 from
every 3 sections of fat perithymic tissue inclusion. The
presence of germinal centers, also named active thymic
tissue, was investigated with monoclonal antibodies
against CD23 [10]. Mouse monoclonal anti-human
antibodies specific for CD23 (clone 1B12, Novocastra,
UK) were used at a 1:100 dilution. Cytoplasmic staining
with anti-human CD23 was scored as positive by an ex-
perienced pathologist.Follow-up
Patients were followed in the dedicated MG unit by the
same team of surgeons and neurologists every 3 months
within the first year and then every 6 months. Patients
continued to receive medical therapy (i.e., anticholines-
terase or steroids), which was progressively reduced and
eventually quitted in the absence of symptoms. No spe-
cific immunosuppressive drug was used. The thera-
peutic effect and symptomatic response to the different
therapies was established for each patient according
to the MG Foundation of America (MGFA) post-
interventus status classification [15]. CSR was defined
as no symptoms or signs of MG at careful examination
for at least 12 months achieved without therapy. Im-
provement was defined as amelioration of MG-related
symptoms (clinical) or a long-lasting decrease in MG
therapy (pharmacologic). Patients whose MG symp-
toms or administered medication dosages were stable
were scored as ‘unchanged’. Equally, those patients
whose symptoms became more serious or required an
increase in medical therapy, were all defined as having‘worsened disease’. PET was routinely repeated at one
year follow-up and evaluated by the same physicians.
Statistical analysis
Preliminary descriptive analysis of variance was performed
for all variables to identify non-normal distribution or in-
correct data. Non-parametric tests were used and data
were expressed as median and interquartile range. All ana-
lyses were performed in SPSS statistical package (SPSS
Inc., Chicago, IL). Results were considered significant for
p < 0.05. Continuous variables were correlated by Spearman
test. Prognostic evaluation was conducted by univariate
and multivariate analysis selecting as primary outcome the
improvement at the end of follow up.
CSR rate was defined as number of patients asymp-
tomatic and off-medications for at least 12 months over
total number of patients evaluated. Kaplan-Meier esti-
mate of time to CSR was determined. Time to CSR was
defined as time from operation day to first date of CSR.
Similarly, those patients who had not achieved CSR were
censored and their consoring time was defined as time
from operation to most recent patient contact. Univariate
and multivariate survival analyses were performed by the
log rank test and Cox regression, respectively, in order to
evaluate the impact of several preoperative and operative
factors on time to CSR. To determine the best cutoff value
for the thymic and perithymic SUV, we performed the
Kaplan-Meier analysis for CSR using several different cutoff
values, choosing the one returning the larger separation.
The choice was confirmed by the analysis of martingale re-
siduals from the null Cox model (not showed).
Results
Perioperative complications
No patient died in the perioperative period. Two patients
(4.2%) suffered from pneumonia with pleural effusion and
one patient who had an episode of atrial fibrillation with
spontaneous resolution in the second post-operative day.
Mean hospital time was 4.5 ± 2.1 and 2.6 ± 2.2 days, re-
spectively (p = 0.03). One patient (2.1%) developed a post-
operative myasthenic crisis, which needed intubation and
subsequent treatment with plasmapheresis.
Histological findings
Histological examination showed the presence of atrophic
thymus gland in 23 patients (34%), hyperplastic in 27
patients (40%) and normal thymic tissue in 18 patients
(26%). The presence of thymic germinal centers was de-
tected in 43 (63%) patients. These centers were signifi-
cantly associated with hyperplastic thymus [21/27 (77%)
Vs normal 11/18 (61%) Vs atrophic 1/22 (4%), p < 0.0001].
Ectopic thymic tissue was detected in 37 patients (54%)
and most of these (23/37, 62%) presented ectopic germinal
centers. They were significantly associated with atrophic
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5/18 (28%), p = 0.002]. Neither circulating anti-AchR Ab
nor MG score were significantly correlated with thymic
histology (data not showed).
SUV assessment
MG patients showed an increased SUV in both thymic
and perithymic tissue compared to results obtained in
108 same-aged non-myasthenic and non-oncologic pa-
tients who performed PET in the same period: thymic
SUV 2.5 (2.2-4.1) Vs 1.2 (0.7-1.6), p = 0.009 and peri-
thymic SUV 1.6 (1.1-2.7) Vs 0.9 (0.6-1.4), p = 0.02.
Thymic SUV was significantly higher in presence of
thymic germinal centers [3.5 (2.4-5.0) Vs 2.1 (1.4-2.5); p =
0.021] (Figure 2). Furthermore, it resulted significantly
correlated with MG score (rho 0.289; p = 0.017), while it
was only marginally correlated with titer for anti-AchR AbFigure 2 Thymic and perithymic SUV correlations with major patholo
Significance was calculated by Kruskal-Wallis or Mann–Whitney when indic(rho 0.129; p = 0.05). No additional associations between
thymic SUV and other clinical variables was detectable.
Perithymic SUV associated to atrophic thymus was
significantly higher (p = 0.021) [2.7 (1.4-3.2)] compared
to hyperplastic [1.6 (1.2-3.3)] or normal [1.3 (0.9-2.0)]
thymus (Figure 2). In addition, it was even further in-
creased in presence of ectopic thymic tissue [2.7 (1.7-
3.2) Vs 1.3 (1.0-1.5); p = 0.009], especially when housing
germinal centers [3.1 (2.7-3.5) Vs 1.3 (0.9-1.7); p =
0.001] (Figure 2). Increased perithymic SUV allowed us
to remove ectopic thymic islets sited in aortopulmonary
window (n = 2), anterior mediastinum (n = 1) and right
pericardiophrenic angle (n = 1) in patients with atrophic
thymus. All these islets were unsuspected on the basis
of a simple CT scan.
At one year follow-up, PET showed a significant decre-
ment of SUV activity in residual mediastinal area [1.1gic variables. Data are indicated as median and interquartile ranges.
ated.
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activity.
Long-term outcomes
No patient was lost during follow-up. The average time
for each patient was equal to 49 (25–68) months (range
12–96). During the study, 42 patients (62%) demonstrated
an improvement of the MG symptoms according to the
MGFA post-interventus status. CSR occurred in a total of
24 subjects (35%), 17 of whom within 60 months from the
procedure (Table 2). The Kaplan-Meier curves are shown
in Figure 3. CSR rate was 31% at 60 months and 64% at
90 months from thymectomy, respectively. Median time
to CSR was 73 months. Histology (p = 0.061), MGFA Class
(p = 0.187) and surgical approach (p = 0.674) did not influ-
ence CSR. Whereas the presence of ectopic thymus tissueTable 2 Univariate analysis of factors predicting the improve
MGFA Postinterventus status improvem





<12 months 12 8





Class I 3 3
Class II 24 16
















No 33 12(p = 0.045) especially when hosting germinal centers (p =
0.036) were significantly correlated with CSR.
Preoperative thymic SUV was not clearly associated
with CSR (effect shown in Figure 3 using a cutpoint at
3.5, p = 0.083). Higher values of perithymic SUV (2.1 or
more Vs less than 2.1) were associated with lower inci-
dence of CSR although this effect did not reach conven-
tional statistical significance (p = 0.052).
Cox regression analysis showed that ectopic tissue with
germinal centers was the most powerful yet not-
significant prognostic factor (p = 0.065, Wald = 3.446,
Exp = 3.952, 95% CI = 0.926-1.671).
Discussion
PET has been already used to study the thymus in the
radiologic evidence of an abnormal mass [14]. However,ment or complete remission within 5 years
ent Complete Remission
p-value Yes (n = 17) No (n = 51) p-value
8 23
0.071 9 28 0.888
10 10
0.068 7 41 0.054
8 28
0.424 9 23 0.342
1 5
0.674 10 30 0.868
6 16
11 36
0.123 6 15 0.449
5 22
0.045 5 18 0.274
7 11
8 25
0.191 9 26 0.889
5 32
0.024 12 19 0.024
2 21
0.009 15 30 0.037
Figure 3 Kaplan-Meier remission curve and log rank test for different variables.
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logical activity in a non-thymomatous thymus in patients
with MG. According to our hypothesis, these patients
may present a metabolically active mediastinal area that
produces anti-AchR Ab and these regions might reveal a
more elevated glucose uptake on PET.
Our data evidenced higher SUVs in both thymic and
perithymic areas from MG patients compared to normal
standard values of our control group. Furthermore, we
highlighted a correlation between the thymic SUV and
the presence of thymic germinal centers. Thymic SUV
also disclosed a correlation with MG score and margin-
ally with anti-AchR Ab titer.
We experienced a significant correlation between peri-
thymic SUV and the presence of ectopic thymic tissue,
showing higher values whenever this tissue hosted ger-
minal centers. Furthermore, in atrophic histology peri-
thymic values were higher than the actual thymic ones.
The discovery of ectopic thymic tissue [9] and mainly of
ectopic germinal centers [10,11,20] in surgical specimens
may obstacle CSR.
This potential ability of PET/CT in discovering tissue
with intense immunologic activity might delineate a pre-
operative role for this investigation. Patients disclosing
intense thymic activity might be operated on with good
results. Conversely, the evidence of consistent perithy-
mic activity should alert the surgeon about the need of a
more extended resection volume and the possibility of
more difficult remission.
PET has still a major limitation in the resolving
power of the method [21] and we mainly attribute to
this inconvenience the lack of significance in predicting
CSR. SUV measure of perithymic areas may be some-
what undefined due to the indetermination of perithy-
mic boundaries and to heterogeneity of anatomical
structure in it. Furthermore the current devices can
only highlight areas in which the concentration of more
germinal centers exceeds the extension of the middle
square centimeter [22]. A germinal center is a very
small set of cells (i.e. thymocytes and lymphocytes) that
by itself constitutes a microenvironment with its me-
tabolism and its source of supply nutritive. This could
explain why in the hyperplasia, where the germinal cen-
ters are organized into areas, the SUV is higher, while
in the perithymic fat, even in presence of ectopic ger-
minal centers, the SUV is less high. This imprecise
evaluation might justify why an elevated SUV was not
correlated to a significant statistical difference in symp-
toms amelioration and CSR.
The retrospective nature is an evident limitation of
this study, however this should be considered only as an
observational study to assess the feasibility of future
more structured investigations. Surgical group allotment
based on the patient’s choice is usually considered amajor bias but, as above mentioned, the comparison of
two different approaches was not the purpose of the study.
We have already mentioned the limitation of image reso-
lution and the difficulty in outlining and measuring SUV
in perithymic areas. These potential flaws were mitigated
by the homogeneous evaluation conducted by a task
force of experienced PET evaluators. The increasing
PET ability to trace metabolic maps might become in a
relatively short future a helpful device in detecting the
presence of these active areas and better orientating
surgical resection.
Conclusions
We can conclude that SUV resulted more elevated in MG
patients in both thymic and perithymic areas. Thymic
SUV was significantly correlated with the presence of ger-
minal centers. Perithymic SUV resulted significantly corre-
lated with the discovery of ectopic active thymic tissue.
Unfortunately the resolution-power of PET did not yet
allow the demonstration of a correlation with MG out-
comes. On these bases and due to the high cost of the
exam at present there is not a consistent reason to use it
out from study protocols. Nevertheless the potential role
of SUV in evidencing active ectopic tissue might be
worthy of further investigations.
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